Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Autoimmune Drugs Market: By Drug Class, By Distribution Channel and Geography
Autoimmune Drugs Market: By Drug Class, By Distribution Channel and Geography
Autoimmune Drugs Market was valued at US$ 109,834 million in 2023 and is projected to reach US$ 153,321 million by 2030, and poised to grow at a CAGR of 4.3% during 2024 to 2030. The immune system protects the body from the infections and diseases. In autoimmune disorders low or overactivity may appear. There is no exact causes of autoimmune diseases are identified. In response to unknown trigger, immune system produces antibodies that instead of fighting infections, attacks body own tissues. There are more than 80 autoimmune diseases are there and diagnosis varies from disease to disease based on the type of disease. Global Autoimmune Drugs market is driven by government initiatives towards increasing awareness in public about autoimmune disorders.
In addition, increase in R&D investments and rising prevalence of autoimmune disorders are expected to boost the global autoimmune disease diagnostics market over the forecast period. Lack of standard treatment options, stringent regulatory framework may hinder the market for Autoimmune Drugs market globally.Market players are collaborating in order to develop the new molecules for the autoimmune diseases and further increasing their market portfolio. Furthermore, government and non-profit organizations are taking initiatives to increase the awareness and involving in development of drugs for autoimmune diseases.
Study Period
2024-2030Base Year
2023CAGR
4.3%Largest Market
North AmericaFastest Growing Market
Asia-Pacific
Global Autoimmune Drugs market is expected to grow at significant rate owing to growing rates of autoimmune diseases. According to National Multiple Sclerosis Society (MS), approximately, 2.3 Mn people are living with multiple sclerosis worldwide. The market is composed of multinational and local companies involved in offering Autoimmune Drugs. Major players are involving in R&D for development and introduction of new drugs into the market.
Geographically Autoimmune Drugs Market is segmented as Latin America, North America, Asia- Pacific, The Middle East & Africa and Europe. North America expected to be major market for Autoimmune Drugs owing to increase in prevalence of autoimmune disorders, presence of many market players, and government initiatives to promote the autoimmune disease awareness. Europe is expected to be another major market for global Autoimmune Drugs because of growing awareness and rising prevalence of autoimmune diseases. Asia Pacific expected to grow at faster rates owing to expansion of MNC's into the developing countries of the regions such as India and increase in R&D investment.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 109,834 million |
|
Market Size in 2030 |
US$ 153,321 million |
|
Market CAGR |
4.3% |
|
By Drug Class |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The autoimmune drugs market size was valued at US$ 109,834 million in 2023 and is projected to reach US$ 153,321 million by 2030, and poised to grow at a CAGR of 4.3% during 2024 to 2030.
The Autoimmune Drugs Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Asia Pacific is the fastest-growing for Autoimmune Drugs Market
| 1.Executive Summary |
| 2.Global Autoimmune Drugs Market Introduction |
| 2.1.Global Autoimmune Drugs Market - Taxonomy |
| 2.2.Global Autoimmune Drugs Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3.Global Autoimmune Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Autoimmune Drugs Market Analysis, 2019-2023 and Forecast 2024-2030 |
| 4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Autoimmune Drugs Market By Drug Class, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 5.1. Immunosuppressanta's |
| 5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Anti-Inflammatory Drugs |
| 5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Corticosteroids |
| 5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Nonsteroidal anti-inflammatory drugs |
| 5.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Biologics |
| 5.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Autoimmune Drugs Market By Distribution Channel, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 6.1. Hospital Pharmacy |
| 6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Online Pharmacy |
| 6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Retail Pharmacy |
| 6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Autoimmune Drugs Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Autoimmune Drugs Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 8.1. Drug Class Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Immunosuppressanta's |
| 8.1.2.Anti-Inflammatory Drugs |
| 8.1.3.Corticosteroids |
| 8.1.4.Nonsteroidal anti-inflammatory drugs |
| 8.1.5.Biologics |
| 8.2. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacy |
| 8.2.2.Online Pharmacy |
| 8.2.3.Retail Pharmacy |
| 8.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Autoimmune Drugs Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 9.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Immunosuppressanta's |
| 9.1.2.Anti-Inflammatory Drugs |
| 9.1.3.Corticosteroids |
| 9.1.4.Nonsteroidal anti-inflammatory drugs |
| 9.1.5.Biologics |
| 9.2. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacy |
| 9.2.2.Online Pharmacy |
| 9.2.3.Retail Pharmacy |
| 9.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 10.Asia Pacific (APAC) Autoimmune Drugs Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Immunosuppressanta's |
| 10.1.2.Anti-Inflammatory Drugs |
| 10.1.3.Corticosteroids |
| 10.1.4.Nonsteroidal anti-inflammatory drugs |
| 10.1.5.Biologics |
| 10.2. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacy |
| 10.2.2.Online Pharmacy |
| 10.2.3.Retail Pharmacy |
| 10.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Autoimmune Drugs Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Immunosuppressanta's |
| 11.1.2.Anti-Inflammatory Drugs |
| 11.1.3.Corticosteroids |
| 11.1.4.Nonsteroidal anti-inflammatory drugs |
| 11.1.5.Biologics |
| 11.2. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacy |
| 11.2.2.Online Pharmacy |
| 11.2.3.Retail Pharmacy |
| 11.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Autoimmune Drugs Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Immunosuppressanta's |
| 12.1.2.Anti-Inflammatory Drugs |
| 12.1.3.Corticosteroids |
| 12.1.4.Nonsteroidal anti-inflammatory drugs |
| 12.1.5.Biologics |
| 12.2. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacy |
| 12.2.2.Online Pharmacy |
| 12.2.3.Retail Pharmacy |
| 12.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Allergan, Inc. (S.) |
| 13.2.2.AbbVie Inc., (U.S.) |
| 13.2.3.Takeda Pharmaceutical Company Limited (Japan) |
| 13.2.4.Bayer AG (Switzerland) |
| 13.2.5.Pfizer Inc. (US) |
| 13.2.6.Reddys (India) |
| 13.2.7.Novartis (Switzerland) |
| 13.2.8.Sanofi Avemtis (France) |
| 13.2.9.Eli Lilly (US) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.